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Abstract
Variability among individuals in the severity of fragile X syndrome (FXS) is influenced by epigenetic methylation mosaicism,
which may also be common in other complex disorders. The epigenetic signal of dense promoter DNA methylation is
usually associated with gene silencing, as was initially reported for FMR1 alleles in individuals with FXS. A paradox arose
when significant levels of FMR1 mRNA were reported for some males with FXS who had been reported to have
predominately methylated alleles. We have used hairpin-bisufite PCR, validated with molecular batch-stamps and barcodes,
to collect and assess double-stranded DNA methylation patterns from these previously studied males. These patterns
enable us to distinguish among three possible forms of methylation mosaicism, any one of which could explain FMR1
expression in these males. Our data indicate that cryptic inter-cell mosaicism in DNA methylation can account for the
presence of FMR1 mRNA in some individuals with FXS.
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Introduction
Epigenetic mosaicism strongly influences the variable pheno-
types characteristic of at least two neurodevelopmental disorders:
fragile X syndrome (FXS) and Rett syndrome [1,2,3,4,5,6]. FXS is
characterized by a broad profile of impairment including
intellectual disabilities and comorbidity with autism (see review
[7]). Current frequency figures for FXS range from 1:2500–8000
in females and 1:4000 in males in the general population
[8,9,10,11].
The molecular epigenetic signature of FXS includes dense DNA
methylation at the FMR1 promoter. Dense methylation of
promoter regions is a common feature of silenced genes [12].
Such silencing was initially reported also to hold for abnormally
methylated FMR1 alleles in individuals with FXS [13]. In FXS,
abnormal methylation can occur within the promoter region of
alleles that contain an expanded CGG repeat [13]. The
transcriptional status of FMR1 is an important variable in the
diagnosis and prognosis of FXS, and is especially informative
because of frequent examples of inter-cell methylation mosaicism
in samples routinely used for diagnosis [2,3,14,15]. The most
severely affected males are typically those whose alleles are densely
methylated at this locus in all cells sampled; such males have
typically been thought not to express FMR1 mRNA. A paradox
arose when Tassone and colleagues reported significant levels of
FMR1 mRNA in the majority of individuals from a cohort of
males with FXS found to have methylated, full mutation FMR1
alleles, and to lack subpopulations of premutation alleles [16].
These individuals showed no evidence of correspondence between
levels of FMR1 mRNA and the severity of the fragile X phenotype.
Large CGG tracts in the 59 region of mRNAs transcribed from full
mutation FMR1 alleles, and even in the premutation range, have
been found to inhibit protein synthesis [17,18]. Thus, even in the
presence of an unmethylated, full mutation allele, these individuals
do not express appreciable levels of FMR1-encoded protein,
FMRP, and do not have phenotypes markedly different from those
of males who lack FMR1 mRNA.
Here, we address a more basic problem in molecular biology.
Are certain types of DNA methylation patterns on heavily
methylated promoters permissive of RNA transcription? One
possible explanation for the unexpected findings of Tassone and
colleagues is that clinical assays, and most research protocols that
are designed to ascertain methylation status, including Southern
hybridization, are not able to detect all possible types of
methylation mosaicism. We reasoned that if methylation mosai-
cism were permissive for FMR1 expression, then double-stranded
DNA methylation patterns of the FMR1 promoter might reveal
mosaicism of an unusual form not previously assessed in FXS.
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Using hairpin-bisulfite PCR with batch-stamps and barcodes we
searched for three possible types of mosaicism by determining
patterns of cytosine methylation on the two complementary
strands of individual DNA molecules, [19]. These methods
provide authenticated information on double-stranded methyla-
tion patterns, and here enabled us to distinguish valid from
contaminant and redundant sequences. The samples described by
Tassone and colleagues thus provide an opportunity to apply new
methods to distinguish among different kinds of mosaicism for
DNA methylation. We collected double-stranded methylation
patterns from DNA of nine males with full mutation alleles
reported to be fully methylated, using a subset of the samples that
Tassone and colleagues used in their 2001 study [16].
Here, we report results of our tests to distinguish among three
possible types of methylation mosaicism: among cells of an
individual (Figure 1A), at CpG sites within an allele (Figure 1B),
between the two strands of an individual DNA molecule
(Figure 1C).
Results
DNA samples used for the Tassone et al. study [16] were
originally evaluated using Southern hybridization analysis, which
showed the presence of hyper-methylated alleles (.200 CGG
repeats). The authors suggested that the FMR1 mRNA transcrip-
tion observed in those subjects could have derived from densely
methylated promoters, in contrast to the typically silenced state of
such methylated promoters [16,12]. Due to the detection limits of
the Southern hybridization approach, an alternative possibility is
that these samples contained alleles with previously unexamined
types of methylation mosaicism that could be permissive for FMR1
transcription.
To address this issue, we have used hairpin-bisulfite PCR [19],
validated with molecular batch-stamps and barcodes [20], to
collect and assess authenticated, double-stranded DNA methyla-
tion patterns at FMR1 in these previously studied males [16]
(Figure 2). These methods here enabled us to distinguish valid
from contaminant and redundant sequences, and thus to provide
more quantitative information on possible methylation mosaicism.
The core of the FMR1 promoter resides within a ,400-
nucleotide sequence immediately upstream of the CGG repeat.
This region contains 52 CpG dinucleotides, some of which overlap
or flank transcription-factor binding elements [21,22] (Figure 3).
To examine these 52 CpG sites, we developed three separate
hairpin-bisulfite PCR assays covering CpG sites 1–22 (hairpin I),
CpG sites 23–32, (hairpin II), and CpG sites 25–52 (hairpin III)
(Figure 3). Detailed results of the methylation analysis of the FMR1
promoter region are reported in Table 1.
Methylation mosaicism among CpG sites
Using the three hairpin assays described above, we obtained
methylation-information for a total of 243 double-stranded DNA
molecules, here termed ‘‘epialleles’’, from males with FXS
(Table 1). Of these molecules, 229 represented methylated
epialleles, while only 14 represented unmethylated epialleles.
These double-stranded data are quantitatively consistent with
our earlier single-stranded methylation data [3]. For the
methylated epialleles, we observed extensive variation in methyl-
ation frequencies among CpG sites. Site-specific frequencies
ranged from 0.5 (site 25) to 1.0 (site 10; Figure 4), similar to the
variation described previously for some regions of FMR1 [3]. The
mean frequency of methylation calculated here from both strands
at CpG sites 1–22 in the males with FXS (0.91; Table 1) is also
similar to our earlier estimates for the top-strand-only data for
males with FXS (0.95) [3]. Our data for methylated, inactive-X
alleles from normal females, reported here, (0.85; Table 1), are
comparable to our previously published results (0.87) [3]. Thus,
the double-stranded and single-stranded methylation data are in
good agreement for these parameters.
To test for consistency of double-stranded methylation data
collected using different hairpin protocols, we compared data at
CpG sites 25 to 32, as ascertained using hairpins II and III, which
Figure 1. Three possible types of mosaicism for cytosine methylation at FMR1. (A) Mosaicism among cells, with either unmethylated (open
squares) or hypermethylated (filled squares) epialleles; (B) mosaicism among CpG sites; and (C) mosaicism between the two strands of an individual
DNA molecule. For the latter two possibilities, each square represents a CpG on a single strand of DNA; filled boxes depict methylated CpGs and open
boxes depict unmethylated CpGs. Arrows represent possible transcriptional activity under each methylation-mosaicism scenario.
doi:10.1371/journal.pone.0023648.g001
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overlapped for these sites. For this comparison, we focused on
samples for which assays with both hairpin II and III were
successful: non-expressing males #2, #23, and female #cF7
(Table 1). The two hairpin assays gave concordant results for all
three individuals regarding inter-cell mosaicism. Male samples #2
and #23 showed only methylated epialleles, and the female
control sample #cF7 showed a mixture of methylated and
unmethylated epialleles, as would be predicted for a female having
one active- and one inactive-X chromosome in each cell.
A comparison of site-specific methylation densities for male #2
and female#cF7 at these eight CpG sites yielded average densities
of methylation that did not differ significantly (p.0.064, 1 d.f.,
x2 = 3.4; p.0.4, 1 d.f., x2 = 0.5, respectively). For the third
individual, male #23, there was a significant difference in average
methylation densities as estimated using hairpins II and III
(p,0.0001, 1 d.f., x2 = 15.8). This p-value is more than ten times
smaller than the significance limit of 0.0015 that is recommended
after the conservative Bonferroni correction for multiple compar-
isons, in this case for the three individuals. We have no
explanation for this significant difference in estimates. In all other
respects, hairpins II and III gave concordant results for this
individual. Unfortunately we were not successful in using both
hairpins on samples from any other individual of this cohort.
Methylation densities obtained with the three different hairpins
and averaged over the 52 analyzed CpG dyads on methylated
epialleles were virtually indistinguishable between FMR1 express-
ing and non-expressing males (0.830 vs. 0.824, respectively). To
further explore possible variation among sites, we next performed
an analysis of variance (ANOVA) for data sets obtained with the
three different hairpins. For hairpin I, there was no significant
effect of FMR1 expression status (p.0.37), or individual (p.0.28).
For hairpin III, the ANOVA indicated no significant effect of
Figure 2. Hairpin–bisulfite PCR at FMR1 (after Miner et al. [20]). The genomic sequence from both strands of the FMR1 promoter, including
the first five of the analyzed analyzed CpG sites, is shown. A hairpin linker, here illustrated for hairpin I, is ligated to both strands of an individual DNA
molecule prior to bisulfite conversion and PCR amplification. The bisulfite-conversion reaction converts cytosine, but not 5-methylcytosine (‘‘me’’), to
uracil, thus preserving information on methylation patterns in genomic DNA. After PCR amplification, uracil residues will appear as thymine; a
cytosine detected in the sequence of a PCR product therefore indicates methylation of that base in the genomic DNA.
doi:10.1371/journal.pone.0023648.g002
Figure 3. Three separate hairpin–bisulfite PCR assays for the FMR1 promoter. Three hairpins were developed to analyze a total of 52 CpG
dyads representing 104 CpGs on both strands of the FMR1 promoter. Small vertical lines depict the distribution of CpG dyads present within the core
region of the human FMR1 promoter and the adjacent track of CGG repeats. Horizontal gray bars above the CpG plot indicate the location of binding
sites for transcription factors and the position of the CGG repeat. Arrows depict three initiation sites for transcription of FMR1.
doi:10.1371/journal.pone.0023648.g003
DNA Methylation Mosaicism in Fragile X Males
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23648
T
a
b
le
1
.
Su
m
m
ar
y
o
f
FM
R
1
-p
ro
m
o
te
r
m
e
th
yl
at
io
n
in
sa
m
p
le
s
fr
o
m
m
al
e
s
w
it
h
FX
S
an
d
fr
o
m
fe
m
al
e
co
n
tr
o
ls
.
In
d
iv
id
u
a
l
m
R
N
A
le
v
e
ls
h
a
ir
p
in
a
ss
a
y
I
(s
it
e
s
1
–
2
2
)
h
a
ir
p
in
a
ss
a
y
II
(s
it
e
s
2
3
–
3
2
)
h
a
ir
p
in
a
ss
a
y
II
I
(s
it
e
s
2
5
–
5
2
)
m
a
le
s
w
it
h
fu
ll
m
u
ta
ti
o
n
e
p
ia
ll
e
le
s
a
n
a
ly
z
e
d
m
e
th
u
n
-
m
e
th
f
m
e
th
a
ll
e
le
s
a
v
e
ra
g
e
d
e
n
si
ty
e
p
ia
ll
e
le
s
a
n
a
ly
z
e
d
m
e
th
u
n
-
m
e
th
f
m
e
th
a
ll
e
le
s
a
v
e
ra
g
e
d
e
n
si
ty
e
p
ia
ll
e
le
s
a
n
a
ly
z
e
d
m
e
th
u
n
-
m
e
th
f
m
e
th
a
ll
e
le
s
a
v
e
ra
g
e
d
e
n
si
ty
m
al
e
1
0
.0
2
5
2
5
0
1
.0
0
0
.9
0
2
4
2
4
0
1
.0
0
0
.8
7
m
al
e
2
0
.0
5
5
0
1
.0
0
0
.6
5
7
7
0
1
.0
0
0
.8
3
m
al
e
6
0
.0
7
7
0
1
.0
0
0
.9
0
m
al
e
2
3
0
.0
2
9
2
9
0
1
.0
0
0
.8
3
1
1
1
1
0
1
.0
0
0
.7
6
m
al
e
3
3
0
.0
1
0
1
0
0
1
.0
0
0
.7
0
m
al
e
3
1
.4
1
6
1
1
5
0
.6
9
0
.9
0
m
al
e
2
0
1
.0
1
7
8
9
0
.4
7
0
.8
9
m
al
e
1
4
0
.8
3
5
3
5
0
1
.0
0
0
.9
2
3
4
3
4
0
1
.0
0
0
.7
3
1
6
1
6
0
1
.0
0
0
.8
4
m
al
e
7
8
0
.7
7
7
0
1
.0
0
0
.6
8
p
o
o
le
d
d
a
ta
fo
r
a
ll
m
a
le
s
w
it
h
fr
a
g
il
e
X
9
3
7
9
1
4
0
.9
1
7
5
7
5
0
0
.7
6
7
5
7
5
0
0
.8
3
n
o
rm
a
l
fe
m
a
le
co
n
tr
o
ls
e
p
ia
ll
e
le
s
a
n
a
ly
z
e
d
m
e
th
u
n
-
m
e
th
f
m
e
th
a
ll
e
le
s
a
v
e
ra
g
e
d
e
n
si
ty
e
p
ia
ll
e
le
s
a
n
a
ly
z
e
d
m
e
th
u
n
-
m
e
th
f
m
e
th
a
ll
e
le
s
a
v
e
ra
g
e
d
e
n
si
ty
e
p
ia
ll
e
le
s
a
n
a
ly
z
e
d
m
e
th
u
n
-
m
e
th
f
m
e
th
a
ll
e
le
s
a
v
e
ra
g
e
d
e
n
si
ty
n
o
rm
al
fe
m
al
e
F1
5
8
3
1
2
7
0
.5
3
0
.8
3
3
2
3
0
2
0
.9
4
0
.6
7
n
o
rm
al
fe
m
al
e
F2
2
8
1
5
1
3
0
.5
4
0
.8
5
n
o
rm
al
fe
m
al
e
F3
7
8
3
3
4
5
0
.4
2
0
.8
7
n
o
rm
al
fe
m
al
e
cF
3
6
3
3
2
3
1
0
.5
1
0
.8
5
2
2
1
6
6
0
.7
3
0
.7
2
n
o
rm
al
fe
m
al
e
cF
4
6
7
3
0
3
7
0
.4
5
0
.8
3
n
o
rm
al
fe
m
al
e
cF
7
5
8
2
0
3
8
0
.3
4
0
.8
6
2
8
2
5
3
0
.8
9
0
.5
7
2
1
1
0
.5
0
0
.5
9
n
o
rm
al
fe
m
al
e
F7
3
5
1
4
2
1
0
.4
0
0
.8
9
n
o
rm
al
fe
m
al
e
cF
9
7
7
0
1
.0
0
0
.5
7
n
o
rm
al
fe
m
al
e
cF
1
0
1
1
1
0
1
0
.9
1
0
.6
0
n
o
rm
al
fe
m
al
e
cF
1
1
5
2
3
0
.4
0
0
.7
5
n
o
rm
al
fe
m
al
e
cF
5
2
4
2
0
4
0
.8
3
0
.6
3
n
o
rm
al
fe
m
al
e
A
6
8
3
0
1
6
1
4
0
.5
3
0
.6
9
p
o
o
le
d
d
a
ta
fo
r
n
o
rm
a
l
fe
m
a
le
s
3
8
7
1
7
5
2
1
2
0
.4
5
0
.8
5
7
8
7
2
6
0
.9
2
0
.6
2
8
3
5
5
2
8
0
.6
6
0
.6
7
Ea
ch
o
f
th
e
th
re
e
h
ai
rp
in
as
sa
ys
w
as
m
o
n
it
o
re
d
fo
r
b
ia
se
d
am
p
lif
ic
at
io
n
o
f
e
it
h
e
r
m
e
th
yl
at
e
d
o
r
u
n
m
e
th
yl
at
e
d
e
p
ia
lle
le
s
u
si
n
g
p
o
o
le
d
d
at
a
o
b
ta
in
e
d
fr
o
m
n
o
rm
al
-f
e
m
al
e
co
n
tr
o
ls
.T
h
e
re
la
ti
ve
FM
R
1
m
R
N
A
le
ve
ls
fo
r
m
al
e
s
w
it
h
FX
S
h
av
e
b
e
e
n
re
p
o
rt
e
d
p
re
vi
o
u
sl
y
[1
6
].
T
h
e
co
lu
m
n
s
la
b
e
le
d
‘‘f
m
e
th
al
le
le
s’
’
g
iv
e
th
e
o
b
se
rv
e
d
fr
e
q
u
e
n
ci
e
s
o
f
m
e
th
yl
at
e
d
e
p
ia
lle
le
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
2
3
6
4
8
.t
0
0
1
DNA Methylation Mosaicism in Fragile X Males
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23648
expression status (p.0.1), but a very significant effect of individual
within the group of non-expressing males (p,0.00001). Thus, we
conclude that this variation in methylation densities is not related
to FMR1 expression but is instead due to variation among
individuals with an inactive FMR1 allele. We have also seen
variation in methylation densities in the control dataset from
normal females, reflecting density of methylation on the inactive-X
chromosome (Table 1).
The analysis for hairpin II was potentially interesting in that it
revealed significant effects of expression group (p,0.01), and
individual (p,0.03). We sought, but did not find, a subset of
methylated sequences that had methylation densities low enough
to permit transcription. The subset of methylated epialleles with
the lowest densities of methylation in this region, identified as
those with #13 of 20 CpGs (considering both strands), averaged
0.55 and 0.60 from expressing (34% of sequences) and non-
expressing males (18% of sequences), respectively. There was no
significant difference in methylation density between the two
groups (p.0.5, 1 d.f., x2 = 0.39). Thus, there was no evidence for
the existence of a subgroup of alleles with overall low-density
methylation that might distinguish expressing from non-expressing
males.
Of the ten CpG sites assayed by hairpin II (CpG sites 23–32), six
are located within binding sites for transcription factors Sp1, Ap2
and USF1 (Figure 3), underscoring their potential relevance to
FMR1 expression. None of these six CpG sites, as ascertained by
hairpin II, had methylation densities that differed significantly
between expressing and non-expressing groups.
CpG dyad 27, which does not overlap with a transcription-
factor binding motif, was the only site assayed with hairpin II that
showed a significant difference in methylation frequency between
expressing and non-expressing males (0.52 and 0.76, respectively;
p,0.02 after Bonferroni correction for multiple comparisons).
However, the subset of low-methylation-density alleles, which
would be most likely to express FMR1, showed no significant
difference between expressing and non-expressing males in
methylation frequency for CpG site 27 (0.29 versus 0.50,
p,0.2); this p-value is well above the 0.005 required for
significance with a Bonferroni correction for multiple compari-
sons. In addition, analysis of data obtained with hairpin III, which
also assays methylation at CpG site 27, provides no evidence for a
pivotal role of this site in FMR1 expression (p#0.48).
In addition, the lack of methylation at site 27 is unlikely to be
sufficient for transcription because an average of 20% of alleles
from non-expressing males sampled in this study have this site
unmethylated. Were this lack of methylation sufficient for
transcription, males with FXS who exhibit this type of site-specific
mosaicism would have FMR1 mRNA at levels greater than 1.4,
assuming a seven-fold average level of elevated transcription for
unmethylated, expanded alleles that approach the size of full
mutation alleles [23]. The limit of detection of FMR1mRNA – less
than 0.01 of normal cells [16] – is substantially below such levels,
establishing that an unmethylated CpG at site 27 of an individual
allele is not sufficient for transcription.
Mosaicism between strands of individual DNA molecules
Hairpin-bisulfite PCR enabled us to ask whether or not
significant differences in DNA methylation densities exist between
the top and bottom strands of individual DNA molecules
(Figure 1C). For example, a marked difference in cytosine
methylation could arise between the two strands of a DNA
molecule if the maintenance DNA methyltransferase, DNMT1,
Figure 4. CpG site-specific methylation frequencies among hypermethylated epialleles. CpG site-specific methylation frequencies among
hypermethylated epialleles as observed in samples from males with FXS who express (open circles), or do not express (filled circles) FMR1. Data were
pooled across hairpin assays I, II, and III. Vertical lines indicate the boundaries of the three different hairpins.
doi:10.1371/journal.pone.0023648.g004
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were inhibited during, or immediately after DNA replication [24].
In such cases, an unmethylated bottom (template) strand could be
transcribed and contribute to an unexpectedly high level of FMR1
mRNA. Such strand-specific methylation at transcribed loci has
been described for a globin gene in chicken embryos [25], and has
recently been reported to account for the transcriptional cycling of
the pS2/TFF1 gene [26]. Hairpin-bisulfite PCR can readily detect
differences in methylation densities between top and bottom
strands of individual molecules [19], and thus enables us to
examine the relationship between top- and bottom-strand
methylation densities [27].
The coding and non-coding strands of double-stranded FMR1
molecules were highly correlated in their methylation densities for
epialleles from both expressing (Figure 5a) and non-expressing
(Figure 5b) males. Of particular relevance is our finding that none
of the 111 methylated molecules from FMR1-expressing individ-
uals had dense methylation on the non-coding, upper strand and
low-density methylation on the coding, lower DNA strand
(Figure 5a). Thus, we can exclude, with 95% confidence, the
existence in FMR1-expressing males of a sub-population larger
than 3.2% of cells that has markedly discordant methylation
patterns between the two strands. This hypothetical 3.2% of cells
would need to transcribe FMR1 to levels more than 30-fold greater
than for normal FMR1 alleles to account for a relative mRNA level
that averages 1.0 in these four expressing males. We conclude that
methylation mosaicism between top and bottom strands of
individual molecules is unlikely to account for FMR1 expression
in these males with FXS.
Detection of inter-cell mosaicism in FMR1-expressing
males with full mutation alleles
Because each male cell carries only one X chromosome, the
presence of both methylated and unmethylated FMR1 alleles in
DNA isolated from an individual male is evidence of inter-cell
mosaicism. For the detection of this type of mosaicism, hairpin I
was the most reliable of the three assays. This hairpin assay yielded
nearly unbiased amplification of methylated and unmethylated
alleles from normal females (Table 1). For the five non-expressing
males, all three hairpin assays yielded only methylated epialleles
(total = 118). The recovery of 118 methylated epialleles and no
unmethylated epialleles excludes with 95% confidence the
existence of a subpopulation of unmethylated epialleles that
constitutes more than 2.5% of cells in the non-expressing males.
Of the four DNA samples of FMR1-expressing males, two
showed evidence of inter-cell methylation mosaicism (males #20
and #3; Table 1). DNA from male #3, previously found to have a
level of FMR1 mRNA of 1.4 relative to the mean for normal males
[16], had 31% (5/16) unmethylated FMR1 alleles. DNA from
male #20, previously found to have a level of FMR1 mRNA of 1.0
[16], had 53% (9/17) unmethylated FMR1 epialleles (Table 1).
Because we validated our hairpin-bisulfite PCR products with
batch-stamps and barcodes [20], we can be confident that each
FMR1 epiallele we analyzed was amplified from a different
genomic template molecule. Likewise, none of our analyzed
epialleles, methylated or unmethylated, arose through contami-
nation or template redundancy. For these two males, the
proportions of unmethylated epialleles reported here are sufficient
to explain the observed levels of FMR1 mRNA. Cells carrying
unmethylated FMR1 epialleles with expanded CGG repeats are
known to transcribe FMR1 at an increased rate (up to 10-fold)
relative to alleles with normal-sized repeats, thereby leading to
unusually high expression levels detected by quantitative RT-PCR
[23,28,29,30]. It is thus clear that males #3 and #20 are inter-cell
methylation mosaics whose levels of FMR1 mRNA are consistent
with their degrees of mosaicism. Such a high level of mosaicism of
unmethylated epialleles could have been missed by earlier
Southern hybridization if the allele sizes were very heterogeneous.
For two of the expressing males, #78 and #14, no
unmethylated epialleles were observed (Table 1). One possible
explanation is that for these males, transcription occurred from a
densely methylated FMR1 promoter, as was suggested previously
[16]. An alternate possibility is that unmethylated epialleles were
present in these individuals, but were not detected. We used a
statistical test to assess this possibility. The DNA sample from
Figure 5. Assessment of methylation mosaicism between the two strands of individual DNA molecules in samples from males with
fragile X syndrome. Data are presented separately for samples from FMR1 mRNA-expressing males (A), and from non-expressing males (B).
Weighted linear regression was used to account for differences in the numbers of CpG sites captured by the three different hairpins. The different
icons of this ‘‘sunflower’’ plot reflect the number of observed epialleles with a given density of methylation on the top and bottom strands. A single
epiallele is represented as a dot, two epialleles with identical methylation densities as a line, three epialleles as a ‘‘three-petal’’ flower, and so on up to
the maximum in our data set of nine molecules.
doi:10.1371/journal.pone.0023648.g005
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expressing male #78 gave only seven informative epialleles with
hairpin II, all of which were methylated. As described in Materials
and Methods, amplification using hairpin II is heavily biased in
favor of methylated alleles, and is thus ineffective at revealing low
levels of unmethylated alleles. With so few informative epialleles,
and such biased amplification of methylated epialleles with hairpin
II, we cannot exclude the possibility that the true frequency of
unmethylated epialleles in DNA sample #78 exceeds 0.1, which,
with overexpression, could account for the observed FMR1mRNA
level of 0.7 reported for this individual. Nonetheless, we cannot
exclude the original proposal [16] that the observed level of FMR1
RNA in this individual arises from methylated epialleles.
For expressing male #14, the larger number of epialleles
available for analysis (85; Table 1), allows a much smaller
probability that there is significant but undetected inter-cell
mosaicism. In order for the observed mRNA level (0.8) to result
from transcription of unmethylated alleles, at least 8–10% of this
individual’s epialleles would have had to have been unmethylated.
The probability that this level of mosaicism existed but was not
detected in our study is less than 0.01. Thus, for this individual,
inter-cell mosaicism is unlikely to account for the observed levels of
FMR1 RNA.
Discussion
The different types of mosaicism for DNA methylation can be
identified and distinguished with new and very sensitive techniques
[19,20]. New methylation data from some of the DNA samples
used by Tassone et al. have allowed us to test for methylation
mosaicism among cells, among CpG sites, and between the two
strands of DNA. Any one of these three possible forms of
methylation mosaicism could, a priori, explain unexpected FMR1
expression in the FXS samples analyzed by Tassone et al. [16].
As described above, we collected double-stranded methylation
patterns from DNA of nine males with full mutation alleles
reported to be fully methylated, using a subset of the samples that
Tassone and colleagues used in their 2001 study [16]. In that
study, four of the males with FXS, for which we here report new
methylation data, were found to have FMR1 mRNA levels ranging
from 0.7 to 1.4, relative to the mean level for normal controls (1.0)
[16]. This result called into question previous reports that
methylation of the FMR1 promoter necessarily results in
transcriptional inactivity [13,31].
One possible explanation for the unexpected finding of Tassone
and colleagues is that most research protocols that are designed to
ascertain methylation status are not able to detect all possible types
of methylation mosaicism. Even for the previously reported inter-
cell mosaicism at the FMR1 locus [3], Southern hybridization does
not readily detect mosaicism in those instances where there is a
broad size distribution of unmethylated epialleles, and could thus
obscure inter-cell mosaicism at FMR1. We reasoned that if
methylation mosaicism were the basis for the observed FMR1
expression, then double-stranded DNA methylation patterns of the
FMR1 promoter might reveal mosaicism of an unusual form not
previously assessed in FXS. We therefore searched for three
possible types of mosaicism using hairpin-bisulfite PCR with
batch-stamps and barcodes [19,20].
Of the three types of methylation mosaicism evaluated in the
current study, only inter-cell mosaicism clearly differed between
the five non-expressing males with FXS as compared to two of the
four FMR1-expressing males analyzed. The variations in methyl-
ation among CpG sites, and between the coding and non-coding
strands of individual DNA duplexes, were similar for expressing
and non-expressing males with FXS.
From two of the FMR1-expressing males, only methylated
alleles were detected. For one of these males (male 78, Table 1),
very few alleles were recovered, all of them from a region with a
strong bias against amplification of unmethylated alleles, rendering
this case uninformative. For this male, neither a high fraction
(0.76) of unmethylated, transcriptionally active alleles, nor the
possibility that all alleles are indeed methylated, can be excluded.
For the other male (male 14, Table 1), numerous epialleles were
recovered from all three regions of FMR1. After correcting for
amplification bias (Text SI), the estimated fraction of unmethy-
lated epialleles is less than 0.01. This hypothetical low level of
unmethylated epialleles cannot readily account for the observed
mRNA expression (0.8) [16], (Table 1).
The finding of mRNA from FMR1 in the sample from male
#14 thus calls for explanations alternate to the inter-cell
methylation-mosaicism hypothesis. It is possible that densely
methylated alleles are amenable to transcription under some
circumstances, since it is known that hypermethylation per se is not
sufficient to block transcription. For example, DNA methylated in
vitro and injected into Xenopus oocytes can be transcribed prior to
accrual of histones [32,33]. It is thus conceivable that reduced
efficiency of chromatin formation underlies the presence of FMR1
mRNA in male #14. Additional samples from this individual as
well as from others in this sample cohort were not available for
further tests of this hypothesis, or indeed, of the formal possibilities
of sample mix-up during collection, storage, and/or assays of
FMR1 epialleles and transcript abundances.
To confirm the generality of our findings, it would be useful to
analyze additional clinical samples from FMR1-expressing fragile
X males diagnosed as having only methylated, full mutation
epialleles. Such samples, however, are rare. Since the time of the
previous publication [16], approximately 200 samples from males
with fragile X who have predominantly methylated full mutation
epialleles have been received by the Fragile X Patient Recruitment
and Evaluation Core at the MIND Institute, University of
California, Davis. Of these samples, the majority have FMR1
mRNA levels less than 0.15 relative to normal males, and none has
an mRNA level greater than 0.4. During the same interval,
approximately 130 additional samples have been received from
fragile X males whose full mutation epialleles had been classified
as inter-cell methylation mosaics. This latter group shows
considerable variability in FMR1 mRNA expression, with levels
overlapping those reported previously [16]. We have not received
any additional samples that both appear fully methylated by
Southern analysis, and have high FMR1 expression. It is possible
that development of new methods for detecting methylation
mosaicism, such as presented in Dahl et al. [34], and here, has
alerted clinical labs to the possibility of cryptic mosaicism, leading
to more sensitive classification of methylation status in males with
full mutation alleles. Due to this lack of relevant samples, it has
been difficult to confirm and extend the finding reported here and
elsewhere [34], that cryptic methylation mosaicism can exist in
males classified clinically as having only methylated, full mutation
FMR1 epialleles.
The presence of cryptic inter-cell methylation mosaicism in
males with full mutations in the FMR1 gene has implications for
the diagnosis and prognosis of FXS. Future clinical and research
studies may benefit from assessing the degree of inter-cell
mosaicism in conjunction with assays for the levels of FMR1
mRNA and protein [35]. Measurement of these epigenetic and
biochemical parameters may contribute to more accurate
prognosis of cognitive function in males with full mutation
FMR1 alleles.
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Materials and Methods
Ethics statement/Subjects
Written consent was obtained from all participating patients and
from female subjects, except for anonymous samples denoted
‘female cF#_’ in Table 1. The consent form was approved by the
Institutional Review Board of the University of California at
Davis. For ‘‘cF#’’ samples the Human Subjects Division at the
University of Washington determined that use of these anonymous
samples does not fall under the federal definition of ‘‘human
subjects research.’’ Use of these samples is therefore not subject to
45 CFR 46 and does not require review by the Institutional
Review Board.
DNA samples
The nine FXS DNA samples used in this study are a subset of
the samples previously described by Tassone and colleagues [16].
We chose to analyze DNA samples from four of the males with
FXS who showed significant levels of FMR1 mRNA expression.
The other five FXS DNA samples used here were from males not
expressing FMR1 mRNA (Table 1). DNAs used in control
experiments were isolated from peripheral blood leukocytes of
twelve females determined to have normal-sized FMR1 CGG
repeats. Four of these DNA samples were provided by F.T. (the
M.I.N.D. Institute), and the remaining eight, designated as ‘cF’,
were from the C.D.L lab collection. It is not known whether or not
skewed X inactivation occurred in any of the female DNA
samples. None of the females examined had SNPs that would
allow us directly to address the question of activation ratio. Indeed,
it is precisely because the nucleotide sequence of the region
examined was identical among the subjects examined that data
from females can serve as a metric of the bias inherent to a given
hairpin assay. Genetic identity at this locus ensures that any
deviations from the 50:50 methylated:unmethylated ratio expected
in data from females can be attributed to the assay itself, rather
than to nucleotide-level differences between the two homologs.
The recovery bias observed for females, for which the true
methylated:unmethylated ratio is known, can therefore be applied
in the interpretation of data from males, for which the true
methylated:unmethylated ratio is unknown.
Hairpin-bisulfite PCR
For each sample, double-stranded genomic DNA was digested
with a restriction enzyme that leaves a single-stranded overhang
near the region to be analyzed. A short hairpin oligonucleotide
linker was ligated to this overhang at the FMR1 locus (Figure 2)
[19]. This hairpin linker contains a defined ‘‘batchstamp’’
sequence that specifies the date of the reaction and the sample
number; a barcode of eight random nucleotides, contained in the
‘‘loop’’ of the hairpin molecule, identifies the original genomic
DNA molecule that served as the PCR template [20]. This
information is indispensable in assembling validated sets of
sequence data that are not corrupted by PCR template
contamination or redundancy [20]. Because of the length of the
region that we wished to study, three different hairpin linkers and
primer sets were necessary to cover the 52 CpG dyads of the
FMR1 promoter (Figure 3).
Protocols were designed to ensure that the CGG repeats of
FMR1 were removed prior to hairpin-linker ligation. The
expanded and sometimes hypermethylated repeats in DNAs from
patients could affect the denaturability of DNAs during PCR
amplification of the FMR1 promoter region, exacerbating any
inherent amplification bias. To eliminate this potential source of
bias, our protocol removes the CGG repeat with appropriate
restriction enzymes as specified below. Methylated and unmethy-
lated FMR1 epialleles from patients and control females are thus
rendered equivalent at the nucleotide-sequence level for the region
analyzed. Hence, it is reasonable to assume, as we do here, that
estimates of amplification bias from normal female FMR1
epialleles can be used to correct for bias in the recovery of
expanded FMR1 epialleles (Text SI).
Following linker ligation, genomic DNA was treated with
bisulfite under conditions that convert unmethylated cytosines to
uracil with very high efficiency, while leaving methylated cytosines
unchanged. After bisulfite conversion, the two strands of linked
genomic DNAs are no longer strongly complementary. This
reduction in strand complementarity allows conventional PCR
amplification of the two now-linked strands of individual DNA
molecules, yielding both top- and bottom-strand methylation
information in a single sequence read [19].
PCR products were subcloned using the TOPO-TA cloning kit
(Invitrogen), and sequenced on an ABI 3100 in the Comparative
Genomics Center of the Department of Biology, the University of
Washington. Resulting sequences were obtained and scored for
CpG-cytosine methylation as described previously [20]. Only
molecules with no more than one failure of conversion for non-
CpG cytosines were used for this analysis, corresponding to a
conversion efficiency exceeding 99%.
The FMR1 promoter is especially difficult to denature in DNA of
individuals with FXS because of augmented levels of DNA
methylation [3]. We used ten denaturation steps during the bisulfite
conversion reaction to achieve good conversion of this CG-rich
promoter. Our protocol for hairpin I has been described previously
[19]; in brief, ,5 ug of DNA was digested with restriction
endonucleases DraIII and AluI prior to ligation of the hairpin
linkers (59PAGCGTAGCDDDDDDDDGCTACGC, where D
represents A, G or T, thus generating random barcodes that are
not altered by bisulfite conversion). Specified differences in the
nonrandom sequences of the hairpin stems, the batch-stamps,
create distinct versions of hairpin I for each individual examined.
Primers used for hairpin I PCR amplification were: 59-
CCTCTCTCTTCAAATAACCTAAAAAC-39 (primer 1), and
59- GTTGYGGGTGTAAATATTGAAATTA-39 (primer 2),
where Y represents C or T. Restriction endonuclease PspGI was
used for hairpin II, to cleave the DNA prior to ligation of the hairpin
linkers (59P- CCTGGTGCACGTTDDDDDDDDAACGTGCA-
39, with variations in the hairpin stem as described above. Primers
used for PCR amplification with hairpin II were: 59- CCTAAC-
TAAAACCRAACCCCC-39, where R represents G or A (primer
1), and 59- GGAGTTGAGYGTTTGATTAGG-39 (primer 2).
PCR for hairpins I and II was performed using HotStarTaq
MasterMix (Qiagen) and 2% DMSO, with denaturation at 95uC
for 15 min., followed by 41 cycles of denaturation at 95uC for
30 sec., annealing at 56uC for 30 sec, and extension at 72uC for
50 sec, followed by a final extension at 72uC for 5 min. For
hairpin III, restriction endonuclease PspGI was used to cleave the
DNA prior to ligation of the hairpin linkers (59P- CCAGGAGC-
GATGCDDDDDDDDGCATCGCT-39, with variations in the
hairpin stem as described above). Primers used for PCR
amplification with hairpin III were: 59- AAAAACRAAAC-
CRAAAAACTAAACCC-39 (primer 1), and 59- ATTTGAAGA-
GAGAGGGYGG-39 (primer 2). PCR conditions were as
described above with annealing at 54uC for 30 sec, and extension
at 72uC for 50 sec, followed by a final extension at 72uC for 5 min.
Common sources of error in data from bisulfite-treated DNA
include biased PCR amplification of individual genomic templates,
and biased cloning of individual PCR products [3]. Both types of
bias can lead to inaccurate estimates of the proportions of
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hypomethylated and hypermethylated epialleles. Our method for
estimating the extent of bias in PCR amplification is included in
Text SI.
Supporting Information
Text SI This document provides additional information
on statistical approaches and equations used to calcu-
late the extent of PCR bias for each of our three
hairpins.
(DOC)
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